<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ISONIAZID (ISONICOTINIC ACID HYDRAZIDE) <img border="0" src="../images/pr.gif"/></span><br/>(eye-soe-nye'a-zid)<br/><span class="topboxtradename">INH, </span><span class="topboxtradename">Isotamine <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Laniazid, </span><span class="topboxtradename">Nydrazid, </span><span class="topboxtradename">PMS Isoniazid <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Teebaconin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antituberculosis agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg, 300 mg tablets; 50 mg/5 mL syrup; 100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Hydrazide of isonicotinic acid with highly specific action against <i>Mycobacterium tuberculosis.</i> Postulated to act by interfering with biosynthesis of bacterial proteins, nucleic acid, and lipids.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Exerts bacteriostatic action against actively growing tubercle bacilli; may be bactericidal in higher concentrations.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of all forms of active tuberculosis caused by susceptible organisms and as preventive in high-risk persons (e.g.,
         household members, persons with positive tuberculin skin test reactions). May be used alone or with other tuberculostatic
         agents.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of atypical mycobacterial infections; tuberculous meningitis; action tremor in multiple sclerosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of isoniazid-associated hypersensitivity reactions, including hepatic injury; acute liver damage of any etiology;
         pregnancy (category C) unless risk is warranted.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Chronic liver disease; renal dysfunction; history of convulsive disorders; chronic alcoholism; persons over 35 y; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Treatment of Active Tuberculosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IM</span> 5 mg/kg (max: 300 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IM</span> 1020 mg/kg (max: 300500 mg/d)<br/><br/><span class="indicationtitle">Preventive Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10 mg/kg up to 300 mg/d or 15 mg/kg 3 times/wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach at least 1 h before or 2 h after meals. If GI irritation occurs, drug may be taken with meals.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li> 				Note: Isoniazid solution for IM injection tends to crystallize at low temperatures; if this occurs, solution should be allowed to
            warm to room temperature to redissolve crystals before use. 			
         </li>
<li>Give deep into a large muscle and rotate injection sites; local transient pain may follow IM injections.</li>
<li>Store in tightly closed, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Drug-related fever, rheumatic and lupus erythematosus-like syndromes, irritation at injection site; hypersensitivity (fever,
      chills, skin eruption, vasculitis). <span class="typehead">CNS:</span> <span class="speceff-common">Paresthesias, peripheral neuropathy,</span> headache, unusual tiredness or weakness, tinnitus, dizziness, hallucinations. <span class="typehead">Special Senses:</span> Blurred vision, visual disturbances, optic neuritis, atrophy. <span class="typehead">GI:</span> Nausea, vomiting, epigastric distress, dry mouth, constipation; hepatotoxicity (<span class="speceff-common">elevated AST, ALT;</span> bilirubinemia, jaundice, <span class="speceff-life">hepatitis</span>). <span class="typehead">Hematologic:</span> <span class="speceff-life">Agranulocytosis</span>, hemolytic or <span class="speceff-life">aplastic anemia</span>, thrombocytopenia, eosinophilia, methemoglobinemia. <span class="typehead">Metabolic:</span> Decreased vitamin B<sub>12</sub> absorption, pyridoxine (vitamin B<sub>6</sub>) deficiency, pellagra, gynecomastia, hyperglycemia, glycosuria, hyperkalemia, hypophosphatemia, hypocalcemia, acetonuria,
      metabolic acidosis, proteinuria. <span class="typehead">Other:</span> Dyspnea, urinary retention (males). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Isoniazid may produce false-positive results using <span class="alt">copper sulfate tests</span> (e.g., <span class="alt">Benedict's solution,</span> <span class="alt">Clinitest</span>) but not with <b>glucose oxidase methods</b> <b></b>(e.g., <b>Clinistix, Dextrostix, TesTape</b>).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Cycloserine,</b> <b>ethionamide</b> enhance CNS toxicity; may increase <b>phenytoin</b> levels, resulting in toxicity; <span class="classification">aluminum-containing antacids</span> decrease GI absorption; <b>disulfiram</b> may cause coordination difficulties or psychotic reactions; <b>alcohol</b> increases risk of hepatotoxicity. <span class="typehead">Food:</span> Food decreases rate and extent of isoniazid absorption; should be taken 1 h before meals. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; food may reduce rate and extent of absorption. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Distributed to all body tissues and fluids including the CNS; crosses placenta. <span class="typehead">Metabolism:</span> Inactivated by acetylation in liver. <span class="typehead">Elimination:</span> 7596% excreted in urine in 24 h; excreted in breast milk. <span class="typehead">Half-Life:</span> 14 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Evident within the first 23 wk of therapy. Over 90% of patients receiving
            optimal therapy have negative sputum by the sixth month.
         </li>
<li>Perform appropriate susceptibility tests before initiation of therapy and periodically thereafter to detect possible bacterial
            resistance.
         </li>
<li>Lab tests: Monitor hepatic function periodically. Isoniazid hepatitis (sometimes fatal) usually develops during the first
            36 mo of treatment, but may occur at any time during therapy; much more frequent in patients 35 y or older, especially
            in those who ingest alcohol daily.
         </li>
<li>Monitor for visual disturbance. An eye examination may be warranted.</li>
<li> 							Note: Inactivation of the drug is genetically determined. Slow inactivation leads to high plasma drug levels and increased risk
            of toxicity. 						
         </li>
<li>Isoniazid-induced pyridoxine (vitamin B<sub>6</sub>) depletion causes neurotoxic effects. B<sub>6</sub> supplementation (1050 mg) usually accompanies isoniazid use.
         </li>
<li>Peripheral neuritis, the most common toxic effect, is usually preceded by paresthesias of feet and hands (numbness, tingling,
            burning). Patients particularly susceptible include alcoholics and patients with liver disease, malnourished patients, diabetics,
            slow inactivators, pregnant women, and older adults.
         </li>
<li>Monitor BP during period of dosage adjustment. Some experience orthostatic hypotension; therefore, caution against rapid positional
            changes.
         </li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Check weight at least twice weekly under standard conditions.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Eating tyramine-containing foods (e.g., aged cheeses, smoked fish) may cause palpitation, flushing, and blood pressure elevation.
            Histamine-containing foods (e.g., skipjack, tuna, sauerkraut juice, yeast extracts) may cause exaggerated drug response (headache,
            hypotension, palpitation, sweating, itching, flushing, diarrhea). 						
         </li>
<li>Withhold medication and notify physician if S&amp;S of hepatotoxicity develop (e.g., dark urine, jaundice, clay-colored stools).</li>
<li>Avoid or at least reduce alcohol intake while on isoniazid therapy because of increased risk of hepatotoxicity.</li>
<li>Withhold all drugs and notify physician of hypersensitivity reaction immediately; generally occurs within 37 wk after
            initiation of therapy.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>